nodes	percent_of_prediction	percent_of_DWPC	metapath
Haloperidol—DRD4—conduct disorder	0.617	0.684	CbGaD
Haloperidol—HTR2A—conduct disorder	0.285	0.316	CbGaD
Haloperidol—Moclobemide—MAOA—conduct disorder	0.0019	0.224	CrCbGaD
Haloperidol—Sertindole—DRD4—conduct disorder	0.00155	0.183	CrCbGaD
Haloperidol—Droperidol—HTR2A—conduct disorder	0.00111	0.131	CrCbGaD
Haloperidol—Sertindole—SLC6A4—conduct disorder	0.00093	0.11	CrCbGaD
Haloperidol—Mazindol—SLC6A4—conduct disorder	0.00093	0.11	CrCbGaD
Haloperidol—Fluspirilene—SLC6A4—conduct disorder	0.000758	0.0894	CrCbGaD
Haloperidol—Sertindole—HTR2A—conduct disorder	0.000715	0.0843	CrCbGaD
Haloperidol—Fluspirilene—HTR2A—conduct disorder	0.000583	0.0687	CrCbGaD
Haloperidol—CYP3A7—Metapathway biotransformation—COMT—conduct disorder	0.000174	0.00194	CbGpPWpGaD
Haloperidol—DRD2—Circadian rythm related genes—DRD4—conduct disorder	0.00017	0.0019	CbGpPWpGaD
Haloperidol—CYP2D6—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.00017	0.00189	CbGpPWpGaD
Haloperidol—CYP2C9—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.000168	0.00187	CbGpPWpGaD
Haloperidol—HTR2B—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.000168	0.00187	CbGpPWpGaD
Haloperidol—HRH1—IL-4 Signaling Pathway—EP300—conduct disorder	0.000166	0.00184	CbGpPWpGaD
Haloperidol—HTR2B—G alpha (q) signalling events—HTR2A—conduct disorder	0.000165	0.00184	CbGpPWpGaD
Haloperidol—HTR2A—SIDS Susceptibility Pathways—MAOA—conduct disorder	0.000164	0.00183	CbGpPWpGaD
Haloperidol—DRD2—GPCR ligand binding—CGA—conduct disorder	0.000163	0.00181	CbGpPWpGaD
Haloperidol—H1F0—Cellular responses to stress—EP300—conduct disorder	0.000162	0.00181	CbGpPWpGaD
Haloperidol—HTR2A—GPCR ligand binding—CGA—conduct disorder	0.00016	0.00178	CbGpPWpGaD
Haloperidol—HRH1—GPCR ligand binding—CGA—conduct disorder	0.00016	0.00178	CbGpPWpGaD
Haloperidol—DRD1—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.000158	0.00177	CbGpPWpGaD
Haloperidol—DRD3—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.000156	0.00174	CbGpPWpGaD
Haloperidol—DRD2—G alpha (i) signalling events—DRD4—conduct disorder	0.00015	0.00168	CbGpPWpGaD
Haloperidol—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EP300—conduct disorder	0.000149	0.00166	CbGpPWpGaD
Haloperidol—CYP1A1—Aryl Hydrocarbon Receptor—EP300—conduct disorder	0.000149	0.00166	CbGpPWpGaD
Haloperidol—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—conduct disorder	0.000148	0.00165	CbGpPWpGaD
Haloperidol—CYP1A2—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.000144	0.0016	CbGpPWpGaD
Haloperidol—HTR1D—GPCR downstream signaling—CGA—conduct disorder	0.00014	0.00156	CbGpPWpGaD
Haloperidol—DRD2—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00014	0.00156	CbGpPWpGaD
Haloperidol—HTR1D—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.000139	0.00155	CbGpPWpGaD
Haloperidol—HTR1D—GPCR ligand binding—DRD4—conduct disorder	0.000139	0.00155	CbGpPWpGaD
Haloperidol—HTR1B—GPCR downstream signaling—CGA—conduct disorder	0.000137	0.00153	CbGpPWpGaD
Haloperidol—HTR2A—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.000137	0.00153	CbGpPWpGaD
Haloperidol—HRH1—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.000137	0.00153	CbGpPWpGaD
Haloperidol—HTR1B—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.000136	0.00152	CbGpPWpGaD
Haloperidol—HTR1B—GPCR ligand binding—DRD4—conduct disorder	0.000136	0.00152	CbGpPWpGaD
Haloperidol—DRD4—GPCR downstream signaling—CGA—conduct disorder	0.000135	0.00151	CbGpPWpGaD
Haloperidol—DRD4—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.000134	0.00149	CbGpPWpGaD
Haloperidol—CYP1A2—Phase II conjugation—COMT—conduct disorder	0.000131	0.00147	CbGpPWpGaD
Haloperidol—KCNH2—SIDS Susceptibility Pathways—EP300—conduct disorder	0.000131	0.00146	CbGpPWpGaD
Haloperidol—HTR2B—GPCR downstream signaling—CGA—conduct disorder	0.000129	0.00144	CbGpPWpGaD
Haloperidol—UGT1A9—PPARA activates gene expression—EP300—conduct disorder	0.000129	0.00144	CbGpPWpGaD
Haloperidol—HTR2B—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.000128	0.00143	CbGpPWpGaD
Haloperidol—HTR2B—GPCR ligand binding—DRD4—conduct disorder	0.000128	0.00143	CbGpPWpGaD
Haloperidol—CYP3A5—Biological oxidations—COMT—conduct disorder	0.000128	0.00142	CbGpPWpGaD
Haloperidol—HTR1D—Signaling by GPCR—CGA—conduct disorder	0.000127	0.00142	CbGpPWpGaD
Haloperidol—CYP3A5—Biological oxidations—MAOA—conduct disorder	0.000127	0.00141	CbGpPWpGaD
Haloperidol—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—conduct disorder	0.000126	0.0014	CbGpPWpGaD
Haloperidol—CYP3A5—Metapathway biotransformation—COMT—conduct disorder	0.000126	0.0014	CbGpPWpGaD
Haloperidol—HTR1B—Signaling by GPCR—CGA—conduct disorder	0.000125	0.00139	CbGpPWpGaD
Haloperidol—DRD4—Signaling by GPCR—CGA—conduct disorder	0.000123	0.00137	CbGpPWpGaD
Haloperidol—DRD1—GPCR downstream signaling—CGA—conduct disorder	0.000122	0.00136	CbGpPWpGaD
Haloperidol—EBP—Metabolism—COMT—conduct disorder	0.000121	0.00135	CbGpPWpGaD
Haloperidol—DRD1—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.000121	0.00134	CbGpPWpGaD
Haloperidol—DRD1—GPCR ligand binding—DRD4—conduct disorder	0.000121	0.00134	CbGpPWpGaD
Haloperidol—CYP1A1—Biological oxidations—COMT—conduct disorder	0.000121	0.00134	CbGpPWpGaD
Haloperidol—EBP—Metabolism—MAOA—conduct disorder	0.000121	0.00134	CbGpPWpGaD
Haloperidol—DRD3—GPCR downstream signaling—CGA—conduct disorder	0.00012	0.00134	CbGpPWpGaD
Haloperidol—CYP1A1—Biological oxidations—MAOA—conduct disorder	0.00012	0.00133	CbGpPWpGaD
Haloperidol—DRD2—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00012	0.00133	CbGpPWpGaD
Haloperidol—CBR1—Metabolism—COMT—conduct disorder	0.000119	0.00133	CbGpPWpGaD
Haloperidol—HTR1D—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.000119	0.00133	CbGpPWpGaD
Haloperidol—DRD3—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.000119	0.00133	CbGpPWpGaD
Haloperidol—DRD3—GPCR ligand binding—DRD4—conduct disorder	0.000119	0.00133	CbGpPWpGaD
Haloperidol—CYP1A1—Metapathway biotransformation—COMT—conduct disorder	0.000119	0.00133	CbGpPWpGaD
Haloperidol—CBR1—Metabolism—MAOA—conduct disorder	0.000119	0.00132	CbGpPWpGaD
Haloperidol—HTR2A—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.000118	0.00131	CbGpPWpGaD
Haloperidol—HRH1—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.000117	0.00131	CbGpPWpGaD
Haloperidol—HTR2B—Signaling by GPCR—CGA—conduct disorder	0.000117	0.00131	CbGpPWpGaD
Haloperidol—EBP—Metabolism of lipids and lipoproteins—EP300—conduct disorder	0.000117	0.0013	CbGpPWpGaD
Haloperidol—HTR1B—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.000117	0.0013	CbGpPWpGaD
Haloperidol—HRH1—G alpha (q) signalling events—HTR2A—conduct disorder	0.000116	0.00129	CbGpPWpGaD
Haloperidol—CBR1—Metabolism of lipids and lipoproteins—EP300—conduct disorder	0.000115	0.00128	CbGpPWpGaD
Haloperidol—DRD4—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.000115	0.00128	CbGpPWpGaD
Haloperidol—CYP3A4—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.000111	0.00124	CbGpPWpGaD
Haloperidol—DRD1—Signaling by GPCR—CGA—conduct disorder	0.000111	0.00123	CbGpPWpGaD
Haloperidol—HTR2B—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00011	0.00122	CbGpPWpGaD
Haloperidol—DRD3—Signaling by GPCR—CGA—conduct disorder	0.000109	0.00122	CbGpPWpGaD
Haloperidol—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—conduct disorder	0.000103	0.00115	CbGpPWpGaD
Haloperidol—DRD1—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.000103	0.00115	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism of lipids and lipoproteins—CGA—conduct disorder	0.000103	0.00114	CbGpPWpGaD
Haloperidol—DRD3—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.000102	0.00114	CbGpPWpGaD
Haloperidol—CYP2C19—Biological oxidations—COMT—conduct disorder	9.87e-05	0.0011	CbGpPWpGaD
Haloperidol—CYP2C19—Biological oxidations—MAOA—conduct disorder	9.8e-05	0.00109	CbGpPWpGaD
Haloperidol—CYP2C19—Metapathway biotransformation—COMT—conduct disorder	9.74e-05	0.00108	CbGpPWpGaD
Haloperidol—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—conduct disorder	9.47e-05	0.00106	CbGpPWpGaD
Haloperidol—CYP1A2—Aryl Hydrocarbon Receptor—EP300—conduct disorder	9.47e-05	0.00106	CbGpPWpGaD
Haloperidol—DRD2—GPCR downstream signaling—CGA—conduct disorder	9.19e-05	0.00102	CbGpPWpGaD
Haloperidol—DRD2—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	9.11e-05	0.00101	CbGpPWpGaD
Haloperidol—DRD2—GPCR ligand binding—DRD4—conduct disorder	9.11e-05	0.00101	CbGpPWpGaD
Haloperidol—CYP2D6—Biological oxidations—COMT—conduct disorder	9.08e-05	0.00101	CbGpPWpGaD
Haloperidol—HTR1D—GPCR ligand binding—HTR2A—conduct disorder	9.07e-05	0.00101	CbGpPWpGaD
Haloperidol—HTR2A—GPCR downstream signaling—CGA—conduct disorder	9.04e-05	0.00101	CbGpPWpGaD
Haloperidol—HRH1—GPCR downstream signaling—CGA—conduct disorder	9.02e-05	0.00101	CbGpPWpGaD
Haloperidol—CYP2D6—Biological oxidations—MAOA—conduct disorder	9.01e-05	0.001	CbGpPWpGaD
Haloperidol—CYP2C9—Biological oxidations—COMT—conduct disorder	9e-05	0.001	CbGpPWpGaD
Haloperidol—HTR2A—GPCR ligand binding—DRD4—conduct disorder	8.96e-05	0.000999	CbGpPWpGaD
Haloperidol—CYP2D6—Metapathway biotransformation—COMT—conduct disorder	8.95e-05	0.000998	CbGpPWpGaD
Haloperidol—HRH1—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	8.94e-05	0.000997	CbGpPWpGaD
Haloperidol—HRH1—GPCR ligand binding—DRD4—conduct disorder	8.94e-05	0.000996	CbGpPWpGaD
Haloperidol—CYP2C9—Biological oxidations—MAOA—conduct disorder	8.94e-05	0.000996	CbGpPWpGaD
Haloperidol—ABCB1—HIF-1-alpha transcription factor network—EP300—conduct disorder	8.89e-05	0.000991	CbGpPWpGaD
Haloperidol—HTR1B—GPCR ligand binding—HTR2A—conduct disorder	8.88e-05	0.00099	CbGpPWpGaD
Haloperidol—CYP2C9—Metapathway biotransformation—COMT—conduct disorder	8.88e-05	0.000989	CbGpPWpGaD
Haloperidol—DRD4—GPCR ligand binding—HTR2A—conduct disorder	8.74e-05	0.000974	CbGpPWpGaD
Haloperidol—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—conduct disorder	8.68e-05	0.000968	CbGpPWpGaD
Haloperidol—DRD4—Circadian rythm related genes—EP300—conduct disorder	8.67e-05	0.000966	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism of lipids and lipoproteins—CGA—conduct disorder	8.4e-05	0.000936	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—CGA—conduct disorder	8.35e-05	0.00093	CbGpPWpGaD
Haloperidol—HTR2B—GPCR ligand binding—HTR2A—conduct disorder	8.35e-05	0.00093	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—CGA—conduct disorder	8.21e-05	0.000915	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—CGA—conduct disorder	8.19e-05	0.000913	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—CGA—conduct disorder	7.96e-05	0.000887	CbGpPWpGaD
Haloperidol—DRD1—GPCR ligand binding—HTR2A—conduct disorder	7.87e-05	0.000877	CbGpPWpGaD
Haloperidol—HTR1D—GPCR downstream signaling—DRD4—conduct disorder	7.86e-05	0.000876	CbGpPWpGaD
Haloperidol—DRD1—Circadian rythm related genes—EP300—conduct disorder	7.8e-05	0.00087	CbGpPWpGaD
Haloperidol—DRD2—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	7.8e-05	0.00087	CbGpPWpGaD
Haloperidol—DRD3—GPCR ligand binding—HTR2A—conduct disorder	7.77e-05	0.000865	CbGpPWpGaD
Haloperidol—DRD3—Circadian rythm related genes—EP300—conduct disorder	7.7e-05	0.000858	CbGpPWpGaD
Haloperidol—HTR1B—GPCR downstream signaling—DRD4—conduct disorder	7.7e-05	0.000858	CbGpPWpGaD
Haloperidol—CYP1A2—Biological oxidations—COMT—conduct disorder	7.69e-05	0.000857	CbGpPWpGaD
Haloperidol—HRH1—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	7.66e-05	0.000854	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism of lipids and lipoproteins—CGA—conduct disorder	7.66e-05	0.000853	CbGpPWpGaD
Haloperidol—CYP1A2—Biological oxidations—MAOA—conduct disorder	7.64e-05	0.000851	CbGpPWpGaD
Haloperidol—CYP1A2—Metapathway biotransformation—COMT—conduct disorder	7.59e-05	0.000845	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—CGA—conduct disorder	7.53e-05	0.000839	CbGpPWpGaD
Haloperidol—CYP1A1—PPARA activates gene expression—EP300—conduct disorder	7.4e-05	0.000824	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—CGA—conduct disorder	7.37e-05	0.000821	CbGpPWpGaD
Haloperidol—ABCB1—Transmembrane transport of small molecules—GABRA2—conduct disorder	7.31e-05	0.000814	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—CGA—conduct disorder	7.25e-05	0.000808	CbGpPWpGaD
Haloperidol—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—conduct disorder	7.24e-05	0.000807	CbGpPWpGaD
Haloperidol—HTR2B—GPCR downstream signaling—DRD4—conduct disorder	7.23e-05	0.000806	CbGpPWpGaD
Haloperidol—HTR1D—Signaling by GPCR—DRD4—conduct disorder	7.14e-05	0.000795	CbGpPWpGaD
Haloperidol—HTR2A—SIDS Susceptibility Pathways—EP300—conduct disorder	7.1e-05	0.000791	CbGpPWpGaD
Haloperidol—HTR1B—Signaling by GPCR—DRD4—conduct disorder	6.99e-05	0.000779	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—CGA—conduct disorder	6.92e-05	0.000772	CbGpPWpGaD
Haloperidol—DRD1—GPCR downstream signaling—DRD4—conduct disorder	6.82e-05	0.00076	CbGpPWpGaD
Haloperidol—DRD3—GPCR downstream signaling—DRD4—conduct disorder	6.73e-05	0.00075	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—CGA—conduct disorder	6.69e-05	0.000746	CbGpPWpGaD
Haloperidol—HTR2B—Signaling by GPCR—DRD4—conduct disorder	6.56e-05	0.000732	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism of lipids and lipoproteins—CGA—conduct disorder	6.54e-05	0.000729	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—CGA—conduct disorder	6.53e-05	0.000728	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—CGA—conduct disorder	6.44e-05	0.000718	CbGpPWpGaD
Haloperidol—DRD1—Signaling by GPCR—DRD4—conduct disorder	6.19e-05	0.00069	CbGpPWpGaD
Haloperidol—DRD3—Signaling by GPCR—DRD4—conduct disorder	6.11e-05	0.000681	CbGpPWpGaD
Haloperidol—GRIN2B—Developmental Biology—EP300—conduct disorder	6.1e-05	0.000679	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—WASF1—conduct disorder	6.03e-05	0.000672	CbGpPWpGaD
Haloperidol—DRD2—GPCR ligand binding—HTR2A—conduct disorder	5.94e-05	0.000662	CbGpPWpGaD
Haloperidol—CYP3A4—Biological oxidations—COMT—conduct disorder	5.94e-05	0.000661	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—WASF1—conduct disorder	5.91e-05	0.000658	CbGpPWpGaD
Haloperidol—CYP3A4—Biological oxidations—MAOA—conduct disorder	5.89e-05	0.000657	CbGpPWpGaD
Haloperidol—DRD2—Circadian rythm related genes—EP300—conduct disorder	5.89e-05	0.000657	CbGpPWpGaD
Haloperidol—CYP3A4—Metapathway biotransformation—COMT—conduct disorder	5.85e-05	0.000652	CbGpPWpGaD
Haloperidol—HRH1—GPCR ligand binding—HTR2A—conduct disorder	5.83e-05	0.00065	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—WASF1—conduct disorder	5.81e-05	0.000648	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—WASF1—conduct disorder	5.55e-05	0.000618	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—WASF1—conduct disorder	5.23e-05	0.000583	CbGpPWpGaD
Haloperidol—EBP—Metabolism—EP300—conduct disorder	5.21e-05	0.00058	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—WASF1—conduct disorder	5.16e-05	0.000575	CbGpPWpGaD
Haloperidol—DRD2—GPCR downstream signaling—DRD4—conduct disorder	5.15e-05	0.000574	CbGpPWpGaD
Haloperidol—HTR1D—GPCR downstream signaling—HTR2A—conduct disorder	5.13e-05	0.000571	CbGpPWpGaD
Haloperidol—CBR1—Metabolism—EP300—conduct disorder	5.12e-05	0.000571	CbGpPWpGaD
Haloperidol—HTR2A—GPCR downstream signaling—DRD4—conduct disorder	5.06e-05	0.000564	CbGpPWpGaD
Haloperidol—HRH1—GPCR downstream signaling—DRD4—conduct disorder	5.05e-05	0.000563	CbGpPWpGaD
Haloperidol—HTR1B—GPCR downstream signaling—HTR2A—conduct disorder	5.02e-05	0.00056	CbGpPWpGaD
Haloperidol—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—conduct disorder	4.99e-05	0.000556	CbGpPWpGaD
Haloperidol—DRD4—GPCR downstream signaling—HTR2A—conduct disorder	4.94e-05	0.000551	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CGA—conduct disorder	4.93e-05	0.000549	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CGA—conduct disorder	4.85e-05	0.000541	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CGA—conduct disorder	4.84e-05	0.000539	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—CGA—conduct disorder	4.84e-05	0.000539	CbGpPWpGaD
Haloperidol—HTR2B—GPCR downstream signaling—HTR2A—conduct disorder	4.72e-05	0.000526	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—DRD4—conduct disorder	4.67e-05	0.000521	CbGpPWpGaD
Haloperidol—HTR1D—Signaling by GPCR—HTR2A—conduct disorder	4.66e-05	0.000519	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—DRD4—conduct disorder	4.6e-05	0.000512	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—DRD4—conduct disorder	4.59e-05	0.000511	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—CGA—conduct disorder	4.57e-05	0.000509	CbGpPWpGaD
Haloperidol—HTR1B—Signaling by GPCR—HTR2A—conduct disorder	4.56e-05	0.000508	CbGpPWpGaD
Haloperidol—DRD4—Signaling by GPCR—HTR2A—conduct disorder	4.49e-05	0.0005	CbGpPWpGaD
Haloperidol—DRD1—GPCR downstream signaling—HTR2A—conduct disorder	4.45e-05	0.000496	CbGpPWpGaD
Haloperidol—DRD3—GPCR downstream signaling—HTR2A—conduct disorder	4.39e-05	0.000489	CbGpPWpGaD
Haloperidol—HTR2B—Signaling by GPCR—HTR2A—conduct disorder	4.28e-05	0.000477	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—DRD4—conduct disorder	4.22e-05	0.00047	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—DRD4—conduct disorder	4.13e-05	0.00046	CbGpPWpGaD
Haloperidol—DRD1—Signaling by GPCR—HTR2A—conduct disorder	4.04e-05	0.00045	CbGpPWpGaD
Haloperidol—DRD3—Signaling by GPCR—HTR2A—conduct disorder	3.99e-05	0.000444	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—WASF1—conduct disorder	3.95e-05	0.00044	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—WASF1—conduct disorder	3.89e-05	0.000433	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—WASF1—conduct disorder	3.88e-05	0.000432	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—DRD4—conduct disorder	3.88e-05	0.000432	CbGpPWpGaD
Haloperidol—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—conduct disorder	3.8e-05	0.000423	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—CGA—conduct disorder	3.74e-05	0.000417	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—DRD4—conduct disorder	3.66e-05	0.000408	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—CGA—conduct disorder	3.65e-05	0.000407	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—DRD4—conduct disorder	3.61e-05	0.000402	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—COMT—conduct disorder	3.59e-05	0.0004	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—MAOA—conduct disorder	3.57e-05	0.000397	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism of lipids and lipoproteins—EP300—conduct disorder	3.46e-05	0.000385	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—CGA—conduct disorder	3.44e-05	0.000383	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—CGA—conduct disorder	3.41e-05	0.00038	CbGpPWpGaD
Haloperidol—DRD2—GPCR downstream signaling—HTR2A—conduct disorder	3.36e-05	0.000374	CbGpPWpGaD
Haloperidol—HRH1—GPCR downstream signaling—HTR2A—conduct disorder	3.3e-05	0.000367	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—HTR2A—conduct disorder	3.05e-05	0.00034	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—COMT—conduct disorder	3.02e-05	0.000337	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—MAOA—conduct disorder	3e-05	0.000334	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—HTR2A—conduct disorder	2.99e-05	0.000334	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—CGA—conduct disorder	2.91e-05	0.000325	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—DRD4—conduct disorder	2.76e-05	0.000308	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—HTR2A—conduct disorder	2.75e-05	0.000307	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—DRD4—conduct disorder	2.72e-05	0.000303	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—DRD4—conduct disorder	2.71e-05	0.000302	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—HTR2A—conduct disorder	2.69e-05	0.0003	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—HTR2A—conduct disorder	2.65e-05	0.000295	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—HTR2A—conduct disorder	2.53e-05	0.000282	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—HTR2A—conduct disorder	2.39e-05	0.000266	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—HTR2A—conduct disorder	2.35e-05	0.000262	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—CGA—conduct disorder	2.25e-05	0.000251	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—COMT—conduct disorder	2.18e-05	0.000243	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—MAOA—conduct disorder	2.17e-05	0.000242	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—COMT—conduct disorder	2.06e-05	0.00023	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—MAOA—conduct disorder	2.05e-05	0.000228	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism of lipids and lipoproteins—EP300—conduct disorder	1.99e-05	0.000221	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—HTR2A—conduct disorder	1.8e-05	0.000201	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—HTR2A—conduct disorder	1.77e-05	0.000197	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—COMT—conduct disorder	1.69e-05	0.000188	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—MAOA—conduct disorder	1.68e-05	0.000187	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—COMT—conduct disorder	1.65e-05	0.000184	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—MAOA—conduct disorder	1.64e-05	0.000182	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism of lipids and lipoproteins—EP300—conduct disorder	1.63e-05	0.000181	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—COMT—conduct disorder	1.55e-05	0.000173	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—MAOA—conduct disorder	1.54e-05	0.000172	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—EP300—conduct disorder	1.54e-05	0.000172	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—COMT—conduct disorder	1.54e-05	0.000172	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—MAOA—conduct disorder	1.53e-05	0.00017	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism of lipids and lipoproteins—EP300—conduct disorder	1.48e-05	0.000165	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—EP300—conduct disorder	1.46e-05	0.000162	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—EP300—conduct disorder	1.43e-05	0.000159	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—EP300—conduct disorder	1.4e-05	0.000156	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—EP300—conduct disorder	1.34e-05	0.000149	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—COMT—conduct disorder	1.32e-05	0.000147	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—MAOA—conduct disorder	1.31e-05	0.000146	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—EP300—conduct disorder	1.3e-05	0.000144	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism of lipids and lipoproteins—EP300—conduct disorder	1.27e-05	0.000141	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—EP300—conduct disorder	1.26e-05	0.000141	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—EP300—conduct disorder	1.25e-05	0.000139	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—COMT—conduct disorder	1.02e-05	0.000113	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—MAOA—conduct disorder	1.01e-05	0.000112	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—EP300—conduct disorder	9.54e-06	0.000106	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—EP300—conduct disorder	9.39e-06	0.000105	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—EP300—conduct disorder	9.37e-06	0.000104	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—EP300—conduct disorder	9.36e-06	0.000104	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—EP300—conduct disorder	8.85e-06	9.86e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—EP300—conduct disorder	7.24e-06	8.07e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—EP300—conduct disorder	7.07e-06	7.87e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—EP300—conduct disorder	6.66e-06	7.42e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—EP300—conduct disorder	6.6e-06	7.36e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—EP300—conduct disorder	5.64e-06	6.29e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—EP300—conduct disorder	4.35e-06	4.85e-05	CbGpPWpGaD
